FLT3 and acute myeloid leukemia: Our observation was further corroborated in three independent, publicly available AML patient datasets (GSE1159 n = 285, GSE6891 n = 521 and GSE15434 n = 251), where PRL-3 expression was consistently observed to be significantly higher in AML patients who were positive for FLT3-ITD mutation compared to those who were negative for FLT3-ITD mutations in three independent datasets (Fig 1B, b–d; Chi-square test; p < 0.001).